Team & history
Publications & IP

Dybly develops pharmaceutical products for patients affected by inflammatory and fibrotic diseases. The company owns several molecules with interesting activity and safety profiles. Dybly research is based on a sequence of hypothesis-driven small molecule drug design with validation by empirical data.

Our scientific results demonstrate activity in the following pathways:

  • BET-Bromodomain (inhibition)
  • Apo A1 (upregulation)
  • Inflammation (downregulation)
  • Fibrosis (downregulation)
  • Blood cancers: MML and AML (suppression of proliferation)

Indications we are interested in:

Fibrotic diseases (lung, liver, heart), Blood cancers, Rheumatoid arthritis and other inflammatory diseases, diseases associated with senescence.

Please contact us to discuss testing these exciting compounds